President Trump has promoted a few different drugs as effective remedies against the novel coronavirus in recent days, but demand for one of them has become so overwhelming that its manufacturer has temporarily shut down its emergency access program to build a broader one, The New York Times reports.
Gilead, which produces remdesivir, a drug that's being studied in large-scale clinical trials across the globe and is currently administered in certain coronavirus cases, said it can no longer grant compassionate use requests because it can't keep up with the number coming in. The company said its emergency access program was limited and never intended for a pandemic, but now that the world is facing one, Gilead intends to set up a broader access program to help more people. "This approach will both accelerate access to remdesivir for severely ill patients and enable the collection of data from all participating patients," the company said in a statement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Swiss bliss: Chenot Palace Weggis takes wellness to the next levelThe Blend Heath retreat on Switzerland's Lake Lucerne offers a mid-winter reset
-
Earth's mini-moon was the moon all alongUnder the radar More lunar rocks are likely floating in space
-
Crossword: February 4, 2025The Week's daily crossword
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
HMPV is spreading in China but there's no need to worryThe Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDAIn the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
-
ACA opens 2025 enrollment, enters 2024 raceSpeed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
